Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library

Larbanoix, Lionel; Burtéa, Carmen; Ansciaux, Emilie; Laurent, Sophie; Mahieu, Isabelle; Elst, Luce Vander; Müller, Robert N.

doi:10.1016/j.peptides.2011.04.026

Cited by 27 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the plaque and the soluble oligomers of amyloids have different morphology, it is not surprising that the protein pull-down by a plague of amyloid correlates poorly with neurodegenerative diseases, which associate with soluble oligomers of amyloid. 12 Moreover, the results in this work imply that, due to its kinetic nature, the process of the aggregation determines the morphology of the aggregates, which helps explain that different labs, sometimes, give paradoxical results regarding to beta-amyloid oligomers. In addition, the protein profiles demonstrate that protein binding of the supramolecular aggregates is promiscuous.…”

mentioning

confidence: 63%

Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules

et al. 2013

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 63%

Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Molecular imaging, which uses small probes (e.g., MRI contrast agents) vectorized to an injured area, offers new tools for diagnosing idiopathic diseases [25–27]. Increasingly, studies are focusing on new targeted approaches to the detection and treatment of inflammation [28–30].…”

Section: Discussionmentioning

confidence: 99%

Phage Display Screening for Tumor Necrosis Factor-α-Binding Peptides: Detection of Inflammation in a Mouse Model of Hepatitis

Sclavons

Burtéa

Boutry³

et al. 2013

International Journal of Peptides

Self Cite

View full text Add to dashboard Cite

TNF-α is one of the most abundant cytokines produced in many inflammatory and autoimmune conditions such as multiple sclerosis, chronic hepatitis C, or neurodegenerative diseases. These pathologies remain difficult to diagnose and consequently difficult to treat. The aim of this work is to offer a new diagnostic tool by seeking new molecular probes for medical imaging. The target-specific part of the probe consists here of heptameric peptides selected by the phage display technology for their affinity for TNF-α. Several affinity tests allowed isolating 2 peptides that showed the best binding capacity to TNF-α. Finally, the best peptide was synthesized in both linear and cyclic forms and tested on the histological sections of concanavalin-A-(ConA-)treated mice liver. In this well-known hepatitis mouse model, the best results were obtained with the cyclic form of peptide 2, which allowed for the staining of inflamed areas in the liver. The cyclic form of peptide 2 (2C) was, thus, covalently linked to iron oxide nanoparticles (magnetic resonance imaging (MRI) contrast agent) and tested in the ConA-induced hepatitis mouse model. The vectorized nanoparticles allowed for the detection of inflammation as well as of the free peptide. These ex vivo results suggest that phage display-selected peptides can direct imaging contrast agents to inflammatory areas.

show abstract

“…The peptides did not show any sign of toxicity in cell culture. The specific interaction of both peptides with amyloid plaques in human brain tissue was demonstrated by immunohistochemistry [49]. …”

Section: Peptides Developed For Ad Diagnosis By In Vivo Imaging Methomentioning

confidence: 99%

Peptides for Therapy and Diagnosis of Alzheimer's Disease

Funke¹,

Willbold

2012

CPD

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis “probable AD” can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-β peptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβ play a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.

show abstract

Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library

Cited by 27 publications

References 39 publications

Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules

Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules

Phage Display Screening for Tumor Necrosis Factor-α-Binding Peptides: Detection of Inflammation in a Mouse Model of Hepatitis

Peptides for Therapy and Diagnosis of Alzheimer's Disease

Contact Info

Product

Resources

About